|
CN103476246A
|
|
Milking device
|
|
EP2547337A1
|
|
Use of anticoagulants in the production of recombinant proteins in the milk of transgenic animals
|
|
NZ568749A
|
|
Use of C1 inhibitor with reduced terminal sialic residues for the prevention of ischemia-reperfusion injury
|
|
AU4486501A
|
|
High dosage parenteral administration of lactoferrin
|
|
AU3425501A
|
|
C1 inhibitor produced in the milk of transgenic mammals
|
|
DE122011000002I1
|
|
HUMAN C1 INHIBITOR MANUFACTURED IN THE MILK OF TRANSGENER MAMMALS
|
|
US7067713B2
|
|
C1 Inhibitor produced in the milk of transgenic non-human mammals
|
|
EP1115742A1
|
|
Purification of fibrinogen from milk by use of cation exchange chromatography
|
|
GB9908447D0
|
|
Human acid alpha glucosidase gene
|
|
GB9908190D0
|
|
Diagnosis of lysosomal storage disorders using saposins and other markers
|
|
GB9828224D0
|
|
Human acid alpha glucosidase gene
|
|
GB9828221D0
|
|
Treatment of Pompe's disease
|
|
EP1017407A2
|
|
Useful properties of human lactoferrin and variants thereof
|
|
EP1736483A2
|
|
Purification of alpha-1 proteinase inhibitor
|
|
NZ501784A
|
|
Transgenic nonhuman mammals capable of secreting a lysosomal protein containing mannose 6-phosphate into milk
|
|
US6713662B1
|
|
Production of collagen in the milk of transgenic mammals
|
|
NZ336981A
|
|
The use of hydrophobic interaction chromatography in the separation of human lactoferrin from a mixture of bovine and human lactoferrins
|
